Bristol-Myers Squibb (BMY) Stock Overview
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
BMY Community Fair Values
Create NarrativeSee what 321 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Bristol-Myers Squibb Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$59.98 |
| 52 Week High | US$62.89 |
| 52 Week Low | US$42.52 |
| Beta | 0.27 |
| 1 Month Change | -1.30% |
| 3 Month Change | 17.15% |
| 1 Year Change | 0.28% |
| 3 Year Change | -11.11% |
| 5 Year Change | -3.54% |
| Change since IPO | 2,707.11% |
Recent News & Updates
Recent updates
Bristol-Myers Squibb: Oncology Franchise Remains A Core Strength
Feb 19We Like Bristol-Myers Squibb's (NYSE:BMY) Earnings For More Than Just Statutory Profit
Feb 18
We Think Bristol-Myers Squibb's (NYSE:BMY) Robust Earnings Are Conservative
May 05
Bristol-Myers Squibb: Extraordinary Dividend And FCF Yields Ready For Recession
Apr 22Bristol-Myers Squibb's Rally Is Well Deserved, Albeit Warranting A Downgrade To Hold
Mar 25Bristol-Myers Squibb: Why I'm Still Bullish
Mar 18Bristol Myers Squibb (BMY): Undervalued Opportunity or Value Trap? A Deep Dive into 2024 Earnings and Fair Value
Total Revenues: $12.3 billion, an 8% increase from the same period in 2023.Bristol-Myers Squibb Stock: A Strong Buy Amid Oncology Success
Feb 21Shareholder Returns
| BMY | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -3.8% | -1.2% | -1.5% |
| 1Y | 0.3% | 26.4% | 21.2% |
Return vs Industry: BMY underperformed the US Pharmaceuticals industry which returned 26.4% over the past year.
Return vs Market: BMY underperformed the US Market which returned 21.2% over the past year.
Price Volatility
| BMY volatility | |
|---|---|
| BMY Average Weekly Movement | 3.5% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: BMY has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BMY's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1887 | 32,500 | Chris Boerner | www.bms.com |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom.
Bristol-Myers Squibb Company Fundamentals Summary
| BMY fundamental statistics | |
|---|---|
| Market cap | US$122.45b |
| Earnings (TTM) | US$7.05b |
| Revenue (TTM) | US$48.19b |
Is BMY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BMY income statement (TTM) | |
|---|---|
| Revenue | US$48.19b |
| Cost of Revenue | US$13.19b |
| Gross Profit | US$35.00b |
| Other Expenses | US$27.95b |
| Earnings | US$7.05b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Apr 30, 2026
| Earnings per share (EPS) | 3.46 |
| Gross Margin | 72.62% |
| Net Profit Margin | 14.64% |
| Debt/Equity Ratio | 244.0% |
How did BMY perform over the long term?
See historical performance and comparisonDividends
Does BMY pay a reliable dividends?
See BMY dividend history and benchmarks| Bristol-Myers Squibb dividend dates | |
|---|---|
| Ex Dividend Date | Apr 02 2026 |
| Dividend Pay Date | May 01 2026 |
| Days until Ex dividend | 21 days |
| Days until Dividend pay date | 50 days |
Does BMY pay a reliable dividends?
See BMY dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/11 10:12 |
| End of Day Share Price | 2026/03/11 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bristol-Myers Squibb Company is covered by 45 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Charles Butler | Barclays |